| Literature DB >> 34732797 |
Audrey Jalabert1, Laura Reininger2, Emmanuelle Berger1,3, Yohann Coute4, Emmanuelle Meugnier1, Alexis Forterre1,2, Elizabeth Errazuriz-Cerda5, Alain Geloen1,3, Myriam Aouadi6, Karim Bouzakri2, Jennifer Rieusset1, Sophie Rome7,8.
Abstract
We have determined the lipid, protein and miRNA composition of skeletal muscle (SkM)-released extracellular vesicles (ELVs) from Ob/ob (OB) vs wild-type (WT) mice. The results showed that atrophic insulin-resistant OB-SkM released less ELVs than WT-SkM, highlighted by a RAB35 decrease and an increase in intramuscular cholesterol content. Proteomic analyses of OB-ELVs revealed a group of 37 proteins functionally connected, involved in lipid oxidation and with catalytic activities. OB-ELVs had modified contents for phosphatidylcholine (PC 34-4, PC 40-3 and PC 34-0), sphingomyelin (Sm d18:1/18:1) and ceramides (Cer d18:1/18:0) and were enriched in cholesterol, likely to alleviated intracellular accumulation. Surprisingly many ELV miRNAs had a nuclear addressing sequence, and targeted genes encoding proteins with nuclear activities. Interestingly, SkM-ELV miRNA did not target mitochondria. The most significant function targeted by the 7 miRNAs altered in OB-ELVs was lipid metabolism. In agreement, OB-ELVs induced lipid storage in recipient adipocytes and increased lipid up-take and fatty acid oxidation in recipient muscle cells. In addition, OB-ELVs altered insulin-sensitivity and induced atrophy in muscle cells, reproducing the phenotype of the releasing OB muscles. These data suggest for the first time, a cross-talk between muscle cells and adipocytes, through the SkM-ELV route, in favor of adipose tissue expansion.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34732797 PMCID: PMC8566600 DOI: 10.1038/s41598-021-00983-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Characterization of SkM-derived exosome-like vesicles (ELVs). (A,B) Transmission electron microscopy showing WT-ELVs (A) and OB-ELVs (B) detected with anti-CD81 (yellow arrows = CD81-gold particles (15 nm), the sizes of labelled ELVs are indicated in red). (C) WB to identify SkM-ELVs specific proteins (CD81, TSG101, ALIX) in C2C12 and C2C12-released-ELVs, and in WT-Quad and WT-Quad-released ELVs. The same quantity of proteins was loaded. (D) WB to show that OB-ELVs and WT-ELVs expressed the exosomal marker CD63. (E) WB showing the levels of proteins involved in SkM-ELV release, in WT-Quad vs OB-Quad. (F) Quantification of ELVs released from WT-Quad or OB-Quad estimated from their quantity of proteins (Bradford assay). (G,H) SkM-ELVs size distribution quantified by Nano-tracking analyses. (* = p < 0.05 (student t-test)). WB originals are in Fig. S2.
Figure 2Impact of obesity on SkM-ELV protein profile. The full protein datasets are in Table S2. (A) Pie chart showing the intracellular localizations of the 798 SkM-ELV proteins. Only the significant pathways with more than 150 genes are shown. (B) Pie chart showing the significant GO metabolic pathways controlled by the 798 SkM-ELV proteins. Only the main significant metabolic pathways with more than 15 genes in the pathway are shown. Redundant pathways have been removed. (C) Clustering of the 798 SkM-ELV proteins, based on their abundance, in OB- and WT-ELVs. (D) Volcano plot showing statistical significance (p-values) versus magnitude of changes (fold changes OB/WT expressed in log2). Red and blue dots represent proteins found more abundant in OB-ELVs and WT-ELVs, respectively (p-value ≤ 0.01 and fold change ≥ 2). (E) Clustering focused on the subset of proteins differentially abundant in OB-ELVs vs WT-ELVs. (F) Significant Biological functions associated with the 37 proteins enriched in OB-ELVs vs WT-ELVs.
Figure 3Impact of obesity on SkM-ELV lipid profile. (A,B) TEM images of Quad muscle from WT (A) or OB (B) mice. (C) Quantification of phospholipids, sphingolipids and cholesterol in Gast from WT and OB mice. (D) Quantification of Hmgcr mRNA in WT- and OB-Gast (* = p < 0.05, student t-test). (E) Quantification of phospholipids, sphingolipids and cholesterol in WT-ELVs and OB-ELVs released from Gast. (F) Lipids differentially concentrated in OB-ELVs or OB-GAST vs their respective WT. Data are expressed as % of total PC, or total SM or total Ceramides identified and quantified from the same concentration of starting material. Significant distributions are determined from student t-test (* = p < 0.05, ** = p < 0.01). red: increased vs control; green: decreased vs control.
Figure 4Altered miRNA content in OB-ELVs vs WT-ELV. (A) Venn Diagram showing the number of miRNAs commonly expressed between muscle and SkM-ELVs, or specific to each compartment. Given the low number of animals (n = 4) we have considered only the miRNAs expressed in all mice for each diagram. The mean Ct values of all miRNAs expressed in WT or OB muscle was not significantly different. (B) Correlations between the Ct values of miRNAs commonly identified between SkM-ELVs and Quad. (C) Heatmap showing the differentially concentrated miRNAs in SkM-ELVs or muscle (D), between OB and WT mice. (E) The significant KEGG pathways containing target genes from the 7 OB-ELV miRNAs (in C) were determined by using DIANA miRPath. The 20 most significant KEGG pathways in terms of lowest p-values are shown.
Figure 5Sequence analyses of exported miRNA in SkM-ELVs. (A) SkM-ELV-miRNAs with EXO-motifs[23]. (B) Detailed procedure to identify the A(G/C)U(G/C)U sequence associated with miRNA nuclear localization. Only miRNAs contained in SkM-ELVs with this sequence are shown[26,28]. Validated miRNAs are indicated in red and the associated publications are mentioned in supplementary Table S3.
miRNAs differentially enriched between WT-ELVs vs OB-ELVs (n = 4 animals per group) or between quadriceps muscle of OB vs WT (n = 3).
| miRNA annotations on TLDA | miRBase 20 annotations | TLDA ID | miRBase I.D | Mean WT | SEM WT | Mean OB | SEM OB | Student | fold changes OB/WT | |
|---|---|---|---|---|---|---|---|---|---|---|
| Differentially expressed in SkM-ELVs | mmu-miR-434-5p | 4,395,711 | MIMAT0001421 | 32.71 | 0.25 | ND | ND | 0.000093 | ||
| mmu-miR-340-5p | 4,395,369 | MIMAT0004651 | 32.75 | 0.63 | ND | ND | 0.0015 | |||
| mmu-miR-1 | mmu-miR-1a-3p | 4,395,333 | MIMAT0000123 | 22.92 | 0.33 | 25.21 | 0.32 | 0.002583041 | ||
| mmu-miR-101a | mmu-miR-101a-3p | 4,395,364 | MIMAT0000133 | 28.59 | 0.21 | 30.78 | 0.48 | 0.013 | ||
| mmu-miR-101b | mmu-miR-101b-3p | 4,395,661 | MIMAT0000616 | 28.74 | 0.13 | 30.44 | 0.12 | 0.000091 | ||
| mmu-miR-29b* | mmu-miR-29b-1-5p | 4,395,627 | MIMAT0004523 | 27.90 | 0.20 | 26.92 | 0.15 | 0.011 | ||
| mmu-miR-224 | mmu-miR-224-5p | 4,395,683 | MIMAT0000671 | 32.49 | 0.44 | 30.55 | 0.20 | 0.015 | ||
| Differentially expressed in quadriceps | mmu-miR-434-3p | 4,395,711 | MIMAT0001422 | 28.39 | 0.16 | 26.87 | 0.33 | 0.029234456 | ||
| mmu-miR-495 | mmu-miR-495-3p | 4,381,078 | MIMAT0003456 | 33.41 | 0.15 | 32.19 | 0.18 | 0.007378497 | ||
| mmu-miR-299* | mmu-miR-299a-5p | 4,373,188 | MIMAT0000377 | 31.53 | 0.11 | 30.83 | 0.14 | 0.018629993 | ||
| mmu-miR-200c | mmu-miR-200c-3p | 4,395,411 | MIMAT0000657 | 31.73 | 0.19 | 32.5 | 0.15 | 0.03923314 | ||
| mmu-miR-106b | mmu-miR-106b-5p | 4,373,155 | MIMAT0000386 | 29.41 | 0.15 | 30.21 | 0.2 | 0.039560446 | ||
| mmu-miR-203 | mmu-miR-203-3p | 4,373,095 | MIMAT0000236 | 29.72 | 0.18 | 30.55 | 0.12 | 0.02686222 | ||
| mmu-miR-24 | mmu-miR-24-3p | 4,373,072 | MIMAT0000219 | 21.72 | 0.18 | 22.57 | 0.02 | 0.044287773 | ||
| mmu-miR-146a | mmu-miR-146a-5p | 4,373,132 | MIMAT0000158 | 26.06 | 0.26 | 27.91 | 0.43 | 0.031590388 |
Data are expressed as qRT-PCR Ct values.
The Ct is defined as the number of cycles required for the fluorescent signal to cross the threshold (i.e.; exceeds background level).
Ct levels are inversely proportional to the amount of target nucleic acid in the sample (i.e.; the lower the Ct level the greater the amount of target nucleic acid in the sample).
In italics: miRNAs increased in OB-ELVs vs WT-ELVs; in bold miRNAs decreased in OB-ELVs vs WT-ELVs.
Gene Ontology pathways significantly enriched in genes targeted by quadriceps-released WT-ELV miRNAs.
| GO molecular component | Homo sapiens—REFLIST (20,851) | WT-ELV | WT-ELV (expected) | WT-ELV (fold Enrichment) | WT-ELV (raw P-value) | WT-ELV (FDR) | |
|---|---|---|---|---|---|---|---|
| GO Functions over-represented | ER to Golgi transport vesicle membrane (GO:0012507) | 17 | 15 | 5.55 | 2.7 | 6.43E−03 | 2.68E−02 |
| Dendritic spine (GO:0043197) | 30 | 25 | 9.79 | 2.55 | 7.92E−04 | 4.85E−03 | |
| Neuron spine (GO:0044309) | 30 | 25 | 9.79 | 2.55 | 7.92E−04 | 4.79E−03 | |
| Presynaptic active zone (GO:0048786) | 24 | 20 | 7.83 | 2.55 | 2.51E−03 | 1.29E−02 | |
| PcG protein complex (GO:0031519) | 28 | 20 | 9.14 | 2.19 | 1.07E−02 | 4.15E−02 | |
| Endocytic vesicle (GO:0030139) | 29 | 20 | 9.47 | 2.11 | 1.21E−02 | 4.59E−02 | |
| Transport vesicle membrane (GO:0030658) | 61 | 42 | 19.91 | 2.11 | 3.22E−04 | 2.52E−03 | |
| Postsynapse (GO:0098794) | 126 | 85 | 41.13 | 2.07 | 4.91E−07 | 6.24E−06 | |
| Synaptic membrane (GO:0097060) | 78 | 52 | 25.46 | 2.04 | 1.33E−04 | 1.18E−03 | |
| SNARE complex (GO:0031201) | 39 | 26 | 12.73 | 2.04 | 5.85E−03 | 2.50E−02 | |
| Synaptic vesicle (GO:0008021) | 68 | 45 | 22.2 | 2.03 | 3.97E−04 | 2.88E−03 | |
| Golgi apparatus subcompartment (GO:0098791) | 70 | 46 | 22.85 | 2.01 | 3.27E−04 | 2.44E−03 | |
| Endosome membrane (GO:0010008) | 72 | 47 | 23.5 | 2 | 3.73E−04 | 2.75E−03 | |
| Coated vesicle membrane (GO:0030662) | 46 | 30 | 15.02 | 2 | 4.64E−03 | 2.14E−02 | |
| Postsynaptic specialization (GO:0099572) | 69 | 45 | 22.53 | 2 | 4.38E−04 | 3.01E−03 | |
| Transport vesicle (GO:0030133) | 115 | 75 | 37.54 | 2 | 6.02E−06 | 6.65E−05 | |
| Cortical cytoskeleton (GO:0030863) | 43 | 28 | 14.04 | 2 | 5.50E−03 | 2.47E−02 | |
| Clathrin-coated vesicle (GO:0030136) | 40 | 26 | 13.06 | 2 | 9.21E−03 | 3.66E−02 | |
| Cytoplasmic ribonucleoprotein granule (GO:0036464) | 75 | 48 | 24.48 | 2 | 4.68E−04 | 3.17E−03 | |
| GO Functions under-represented | Mitochondrial protein-containing complex (GO:0098798) | 262 | 50 | 85.53 | 0.58 | 2.66E−04 | 2.28E−03 |
| Condensed nuclear chromosome (GO:0000794) | 145 | 25 | 47.34 | 0.53 | 2.27E−03 | 1.55E−02 | |
| Ribosome (GO:0005840) | 225 | 38 | 73.45 | 0.52 | 6.94E−05 | 6.66E−04 | |
| Myelin sheath (GO:0043209) | 213 | 30 | 69.53 | 0.43 | 2.87E−06 | 3.15E−05 | |
| Respiratory chain complex (GO:0098803) | 80 | 11 | 26.12 | 0.42 | 4.69E−03 | 3.05E−02 | |
| Mitochondrial ribosome (GO:0005761) | 90 | 10 | 29.38 | 0.34 | 4.06E−04 | 3.30E−03 | |
| Synaptonemal structure (GO:0099086) | 97 | 9 | 31.67 | 0.28 | 3.56E−05 | 3.51E−04 | |
| Respiratory chain complex I (GO:0045271) | 49 | 4 | 16 | 0.25 | 2.16E−03 | 1.50E−02 | |
| NADH dehydrogenase complex (GO:0030964) | 49 | 4 | 16 | 0.25 | 2.16E−03 | 1.50E−02 | |
| Immunoglobulin complex (GO:0019814) | 192 | 2 | 62.68 | 0.03 | 3.90E−21 | 1.02E−19 | |
| Immunoglobulin complex, circulating (GO:0042571) | 188 | 1 | 61.37 | 0.02 | 6.31E−22 | 1.69E−20 | |
| 90S preribosome (GO:0030686) | 28 | 0 | 9.14 | < 0.01 | 6.03E−04 | 4.67E−03 |
Target genes predictions are from TargetScan 6.0.
Significant pathways are from PANTHER version 15.0 (PANTHER Overrepresentation Test).
Only functions with more than twofold enrichments (+ or -) are shown.
Figure 6OB-ELVs modulate lipid storage in recipient cells. (A) 3T3-L1 cells were grown and differentiated in 96-wells E-plates and then maintained in DMEM/5% FBS vesicle-free for 2 h before treatment with OB-ELVs or WT-ELVs. Untreated adipocytes were used as control. The curves represent real-time monitoring of the cell index substracted from the cell index at T = 0 (mean delta cell index, every 5 min during 50 cycles then every 15 min) for 72 h. (B) Slopes at T = 72 h (mean values + /- SEM) (n = 8). (C) mRNA levels of genes involved in lipogenesis in differentiated adipocytes at T = 72 h post treatment with OB-ELVs or WT-ELVs. (D) Western-blot showing the oxphos proteins in C2C12 treated for 24 h with OB-ELVs or WT-ELVs (the full gel is shown). (E) mRNA levels of genes involved lipid metabolism in C2C12 treated for 24 h with OB-ELVs or WT-ELVs. For all figures, * = significant p-values (p < 0.05, student t-test).
Figure 7OB-ELVs induced insulin-resistance and atrophy in recipient muscle cells. (A) Quantification of phosphorylated AKT protein on serine serine A-473 by Western-blot in C2C12 treated with SkM-ELVs. Data are expressed in fold p-AKT/total AKT. (B) Quantification of AKT isoforms in C2C12 treated with SkM-ELVs by WB. Data are expressed as ratios of AKT level in treated vs untreated conditions. (C) mRNA levels of genes involved in insulin-stimulated glucose uptake. Data are expressed as arbitrary units. (D) mRNA level of genes involved in muscle atrophy. Data are expressed as arbitrary units.